GlassScriptPhysician profile
Alexandra Greenberg
NPI 1063852101
$11,629.78
in general payments reported to CMS, 2019-2025
41 companies · $2,458 in 2025
The $2,458 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,556 · 2020: $1,023 · 2021: $1,136 · 2022: $1,618 · 2023: $1,695 · 2024: $2,144 · 2025: $2,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,242 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00 · Education: $15.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,242.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
| Education | $15.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,704.36 | 2019-2025 | |
| Janssen Biotech, INC. | $1,900.55 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,031.04 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Scientific Affairs, LLC | $627.89 | 2019-2023 | Stelara |
| Pfizer INC. | $560.11 | 2019-2025 | |
| Celgene Corporation | $491.61 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $431.70 | 2023-2025 | Omvoh, Mounjaro, Zepbound |
| Genzyme Corporation | $392.41 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $309.15 | 2019-2024 | Dificid, Zinplava |
| Takeda Pharmaceuticals U.S.A., INC. | $261.50 | 2020-2025 | Gattex, Entyvio, Eohilia |
| Ardelyx, INC. | $249.77 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $242.07 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $241.33 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $225.81 | 2019-2023 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $202.34 | 2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $165.42 | 2019-2023 | Linzess |
| Amgen INC. | $157.37 | 2023-2025 | Uplizna, Amjevita |
| Davol INC. | $150.00 | 2025 | Phasix Mesh |
| Mallinckrodt Hospital Products INC. | $142.71 | 2025 | Terlivaz |
| Novo Nordisk INC | $119.63 | 2023 | Wegovy |
| Covidien LP | $114.47 | 2019 | |
| Ethicon US, LLC | $112.63 | 2019 | |
| Madrigal Pharmaceuticals | $96.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $85.78 | 2019-2025 | Sucraid |
| Daiichi Sankyo INC. | $80.04 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $74.26 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $73.67 | 2021-2023 | |
| Romark Laboratories, Lc | $55.21 | 2020 | |
| Evoke Pharma, INC. | $52.10 | 2022-2025 | |
| Redhill Biopharma INC. | $41.16 | 2021-2023 | Talicia, Aemcolo |
| Intercept Pharmaceuticals, INC. | $39.04 | 2020 | |
| Celltrion USA INC. | $31.91 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $28.54 | 2021-2025 | Suflave, Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.56 | 2019-2021 | |
| Concordia Pharmaceuticals INC. | $25.42 | 2019 | |
| Aimmune Therapeutics, INC. | $17.99 | 2024 | |
| Shionogi INC | $14.90 | 2019 | |
| Ucb, INC. | $14.83 | 2019 | |
| Vivus LLC | $14.02 | 2025 | Qsymia |
| Mallinckrodt Enterprises LLC | $13.71 | 2019 | |
| Shire North American Group INC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.